The overactivation of PERK-eIF2α phosphorylation, which occurs in several models of human diseases [51], led to the prediction that the pharmacological modulation of the PERK-dependent UPR signaling pathways may contribute to ameliorate the symptoms of X-DC. The gene discussed is EIF2A; the disease is dyskeratosis congenita.